Amgen Inc (AMGN) Receives Buy Rating from William Blair

Amgen Inc. (AMGN) is considered one of the Most Undervalued S&P 500 Stocks to Buy Right Now. William Blair analyst Matt Phipps reiterated a Buy rating on AMGN without a disclosed price target. Recent results from FORTITUDE-101 showed less survival benefit for Bemarituzumab in gastric cancer, but optimism remains for FORTITUDE-102.

Despite setbacks, management of AMGN is focused on the upcoming FORTITUDE-102 trial, combining Bemarituzumab with chemotherapy and Opdivo. Results from this trial are crucial for regulatory approval and market potential. A strong portfolio and flexible strategy indicate positive long-term growth for AMGN.

Amgen Inc. (AMGN) is a biotechnology company specializing in developing medicines for serious diseases with high unmet medical needs. While AMGN shows investment potential, some AI stocks might offer greater upside with lower downside risk. For more information on undervalued AI stocks, refer to the provided link.